News & Updates

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021 by

The anti-PD-1 antibody tislelizumab may help improve patient outcomes vs docetaxel as second- or third-line treatment for advanced or metastatic non–small-cell lung cancer (NSCLC) regardless of histology or PD-L1 expression, interim findings from the phase III RATIONALE 303 study have shown.

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021 by

First-line treatment with the bispecific fusion protein tebentafusp demonstrated an overall survival (OS) benefit in patients with human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma (mUM), according to a phase III, open-label trial presented at AACR 2021.

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021

Beta-1 selective blockers linked to breast cancer risk

15 May 2021

Women using beta-1 selective blockers may be at increased risk of developing breast cancer, with the association showing a dose-response pattern, according to a study.

Beta-1 selective blockers linked to breast cancer risk

15 May 2021

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?

14 May 2021 by

In individuals with resected oesophageal or gastro-oesophageal junction (GEJ) cancer who have received neoadjuvant chemoradiotherapy (CRT), adjuvant nivolumab therapy demonstrated superior efficacy over placebo, according to the CheckMate 577 trial.

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?

14 May 2021

Mobile sensing monitors cancer patients’ behaviour, physiology to predict symptom burden

14 May 2021 by

Digital biomarkers collected by smartphones and wearable sensors may help detect behavioural and physiological changes signalling symptom burden in pancreatic cancer patients before and after surgery, according to a recent study.

Mobile sensing monitors cancer patients’ behaviour, physiology to predict symptom burden

14 May 2021

Topical imiquimod encourages regression of high-grade precancerous cervical lesion

13 May 2021

High-grade squamous intraepithelial lesions of the cervix may regress with weekly application of imiquimod cream, as shown in the results of a phase II study.

Topical imiquimod encourages regression of high-grade precancerous cervical lesion

13 May 2021

Sugary drinks hurt survival in breast cancer

13 May 2021

Frequent consumption of sugar-sweetened soda contributes to an increased risk of death from any cause or due to breast cancer in women, a study suggests.

Sugary drinks hurt survival in breast cancer

13 May 2021

Niraparib PFS benefit in ovarian cancer consistent regardless of time to progression, response to prior chemo

12 May 2021 by

Niraparib maintenance therapy improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of time to progression since penultimate platinum chemotherapy or response to last chemotherapy, according to subgroup analyses of the NORA trial.

Niraparib PFS benefit in ovarian cancer consistent regardless of time to progression, response to prior chemo

12 May 2021

Atezolizumab-bevacizumab combo continues to win in advanced HCC

12 May 2021 by

The combination of the immune checkpoint inhibitor atezolizumab and the angiogenesis inhibitor bevacizumab continues to demonstrate significant clinical benefits vs the oral multikinase inhibitor sorafenib in patients with unresectable hepatocellular carcinoma (HCC), according to updated results from the IMbrave150 trial.

Atezolizumab-bevacizumab combo continues to win in advanced HCC

12 May 2021

Sintilimab shows potential as second-line treatment option for squamous NSCLC

12 May 2021 by

The anti-PD-1 monoclonal antibody sintilimab outperformed docetaxel as second-line treatment for advanced and metastatic squamous non-small-cell lung cancer (NSCLC), according to the results of the phase III ORIENT-3 trial presented at AACR 2021.

Sintilimab shows potential as second-line treatment option for squamous NSCLC

12 May 2021

News & Updates

Filter by Specialty:

Specialty:

Tislelizumab trumps docetaxel in pre-treated NSCLC

Tislelizumab trumps docetaxel in pre-treated NSCLC

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

Beta-1 selective blockers linked to breast cancer risk

Beta-1 selective blockers linked to breast cancer risk

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?

Mobile sensing monitors cancer patients’ behaviour, physiology to predict symptom burden

Mobile sensing monitors cancer patients’ behaviour, physiology to predict symptom burden

Topical imiquimod encourages regression of high-grade precancerous cervical lesion

Topical imiquimod encourages regression of high-grade precancerous cervical lesion

Sugary drinks hurt survival in breast cancer

Sugary drinks hurt survival in breast cancer

Niraparib PFS benefit in ovarian cancer consistent regardless of time to progression, response to prior chemo

Niraparib PFS benefit in ovarian cancer consistent regardless of time to progression, response to prior chemo

Atezolizumab-bevacizumab combo continues to win in advanced HCC

Atezolizumab-bevacizumab combo continues to win in advanced HCC

Sintilimab shows potential as second-line treatment option for squamous NSCLC

Sintilimab shows potential as second-line treatment option for squamous NSCLC